S&R Associates represented Glenmark Pharmaceuticals Limited
S&R Associates is representing Glenmark Pharmaceuticals Limited, a listed pharmaceutical company, in its proposed INR 56.51
S&R Associates represented Glenmark Pharmaceuticals Limited S&R Associates is representing Glenmark Pharmaceuticals Limited, a listed pharmaceutical company, in its proposed INR 56.51 billion sale of 75% of the equity shares of its subsidiary Glenmark Life Sciences Limited, a listed active pharmaceutical ingredients manufacturer, to Nirma Limited. The transaction is subject to...
S&R Associates represented Glenmark Pharmaceuticals Limited
S&R Associates is representing Glenmark Pharmaceuticals Limited, a listed pharmaceutical company, in its proposed INR 56.51 billion sale of 75% of the equity shares of its subsidiary Glenmark Life Sciences Limited, a listed active pharmaceutical ingredients manufacturer, to Nirma Limited. The transaction is subject to customary conditions, including regulatory and shareholder approvals.
The S&R team was led by partners Rajat Sethi and Pratichi Mishra, and included associates Neethu Roy, Samyak Jain and Oshika Nayak on corporate matters; Simran Dhir, head of competition practice, and counsel Akshat Kulshrestha on competition law matters; partner Sumit Bansal and associates Shivani Chhabra and Taranjeet Singh on tax matters; and partner Divyanshu Pandey and associates Shekhar Shrivastava and Ramkrishna Panigrahi on banking and finance matters.